Real-time
Euronext Amsterdam
05:22:07 2024-06-10 am EDT
|
5-day change
|
1st Jan Change
|
24.68
EUR
|
-0.72%
|
|
-3.52%
|
-33.28%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,060
|
5,264
|
3,227
|
2,722
|
2,438
|
1,638
|
-
|
-
|
Enterprise Value (EV)
1 |
6,305
|
102.9
|
-1,450
|
2,722
|
-1,237
|
-1,730
|
-1,335
|
-919.4
|
P/E ratio
|
74.9
x
|
-17.2
x
|
-31.2
x
|
-12.5
x
|
11.5
x
|
-42.2
x
|
-15.8
x
|
-11.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.5
x
|
9.93
x
|
6.65
x
|
5.39
x
|
3.11
x
|
5.24
x
|
5.42
x
|
5.59
x
|
EV / Revenue
|
7.04
x
|
0.19
x
|
-2.99
x
|
5.39
x
|
-1.58
x
|
-5.53
x
|
-4.41
x
|
-3.14
x
|
EV / EBITDA
|
16.5
x
|
-0.64
x
|
11.1
x
|
-13.5
x
|
-
|
16.8
x
|
9.29
x
|
6.59
x
|
EV / FCF
|
1.98
x
|
-0.22
x
|
2.65
x
|
-
|
2.91
x
|
5.71
x
|
2.69
x
|
1.35
x
|
FCF Yield
|
50.5%
|
-457%
|
37.8%
|
-
|
34.4%
|
17.5%
|
37.2%
|
73.9%
|
Price to Book
|
4.19
x
|
1.97
x
|
1.22
x
|
-
|
-
|
0.61
x
|
0.64
x
|
0.74
x
|
Nbr of stocks (in thousands)
|
64,667
|
65,412
|
65,553
|
65,836
|
65,897
|
65,897
|
-
|
-
|
Reference price
2 |
186.5
|
80.48
|
49.22
|
41.35
|
36.99
|
24.86
|
24.86
|
24.86
|
Announcement Date
|
2/20/20
|
2/18/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
895.6
|
530.3
|
484.8
|
505.3
|
783.5
|
312.8
|
302.4
|
292.8
|
EBITDA
1 |
382.7
|
-160
|
-131
|
-202
|
-
|
-102.9
|
-143.7
|
-139.4
|
EBIT
1 |
370.3
|
-178.6
|
-165.6
|
-267.5
|
129
|
-105.1
|
-154.4
|
-168.8
|
Operating Margin
|
41.35%
|
-33.68%
|
-34.15%
|
-52.94%
|
16.46%
|
-33.6%
|
-51.07%
|
-57.66%
|
Earnings before Tax (EBT)
1 |
150.1
|
-309.8
|
-123
|
-215.1
|
-
|
4.881
|
-43.6
|
-75.56
|
Net income
1 |
149.8
|
-305.4
|
-103.2
|
-218
|
211.7
|
-13.26
|
-71.48
|
-99.46
|
Net margin
|
16.73%
|
-57.59%
|
-21.29%
|
-43.14%
|
27.02%
|
-4.24%
|
-23.64%
|
-33.96%
|
EPS
2 |
2.490
|
-4.690
|
-1.580
|
-3.320
|
3.210
|
-0.5889
|
-1.571
|
-2.164
|
Free Cash Flow
1 |
3,186
|
-469.9
|
-547.7
|
-
|
-425.2
|
-302.6
|
-495.9
|
-679.2
|
FCF margin
|
355.77%
|
-88.6%
|
-112.97%
|
-
|
-54.27%
|
-96.75%
|
-163.97%
|
-231.95%
|
FCF Conversion (EBITDA)
|
832.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
2,126.99%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
2/18/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
143.4
|
144
|
137.7
|
274
|
136.2
|
95.12
|
178.9
|
150
|
120
|
334.7
|
62.43
|
60.6
|
60.93
|
64.68
|
55.85
|
55.85
|
EBITDA
|
15.79
|
-
|
-44.04
|
-
|
-
|
-110.8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
10.2
|
-21.1
|
-76.4
|
-97.5
|
-37.6
|
-132.5
|
21.97
|
-10.69
|
-30.23
|
148
|
-33.13
|
-29.36
|
-30.68
|
-27.49
|
-22.97
|
-23.21
|
Operating Margin
|
7.11%
|
-14.65%
|
-55.48%
|
-35.58%
|
-27.61%
|
-139.26%
|
12.28%
|
-7.13%
|
-25.19%
|
44.21%
|
-53.07%
|
-48.46%
|
-50.35%
|
-42.5%
|
-41.13%
|
-41.56%
|
Earnings before Tax (EBT)
1 |
19.09
|
-11.6
|
-18.22
|
-
|
22.25
|
-207.6
|
23.46
|
18.46
|
25.73
|
-
|
22.94
|
-4.637
|
-7.706
|
-16.17
|
5.88
|
5.66
|
Net income
1 |
16.37
|
-13.3
|
-19
|
-
|
21.5
|
-207.2
|
23.21
|
5.101
|
25.83
|
157.6
|
90.22
|
-4.637
|
-7.706
|
-16.31
|
5.88
|
5.66
|
Net margin
|
11.41%
|
-9.24%
|
-13.8%
|
-
|
15.79%
|
-217.84%
|
12.97%
|
3.4%
|
21.52%
|
47.08%
|
144.51%
|
-7.65%
|
-12.65%
|
-25.22%
|
10.53%
|
10.13%
|
EPS
2 |
0.2500
|
-
|
-0.2900
|
-
|
0.3300
|
-3.160
|
-
|
0.0800
|
0.3900
|
2.390
|
-
|
-0.2120
|
-0.1930
|
-0.2830
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5,755
|
5,161
|
4,676
|
-
|
3,675
|
3,368
|
2,973
|
2,558
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
3,186
|
-470
|
-548
|
-
|
-425
|
-303
|
-496
|
-679
|
ROE (net income / shareholders' equity)
|
16.2%
|
-11%
|
-3.89%
|
-
|
7.96%
|
-2.16%
|
-3.59%
|
-5.37%
|
ROA (Net income/ Total Assets)
|
8.82%
|
-5.18%
|
-1.89%
|
-
|
4.66%
|
-3.68%
|
-1.21%
|
-3.78%
|
Assets
1 |
1,698
|
5,892
|
5,455
|
-
|
4,546
|
360.6
|
5,899
|
2,629
|
Book Value Per Share
2 |
44.50
|
40.80
|
40.30
|
-
|
-
|
41.00
|
39.10
|
33.70
|
Cash Flow per Share
2 |
53.40
|
-6.530
|
-7.530
|
-
|
-
|
-2.300
|
-2.600
|
-4.100
|
Capex
1 |
22.4
|
42.5
|
54.2
|
-
|
19.3
|
29.8
|
37.4
|
31.9
|
Capex / Sales
|
2.5%
|
8.02%
|
11.18%
|
-
|
2.46%
|
9.53%
|
12.36%
|
10.91%
|
Announcement Date
|
2/20/20
|
2/18/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
24.86
EUR Average target price
37.03
EUR Spread / Average Target +48.95% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.23% | 1.77B | | +51.85% | 57.87B | | +41.65% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|